Six mice per arm put the disputed PTBP1 conversion route back in the argument
Peisheng Xu's group degraded the PTBP1 protein with antibodies ferried past the blood-brain barrier, and human astrocytes in a dish turned into firing neurons. In living mice, the lineage question is still open.
The Scientist · Science desk
What happened
- A polymer nanogel called Nano-ERASER carried PTBP1-targeting antibodies across the blood-brain barrier into astrocytes and degraded the protein there, which the authors report converts those support cells into neurons.
- In human astrocyte cultures and in organoids grown from human stem cells, treated cells lost their star shape, formed axons, accumulated neuronal proteins and eventually showed synchronous electrical firing.
- The animal test used 12 mice engineered to develop an Alzheimer's-like condition, with half given two intravenous doses of the drug and the other half saline injections.
- Xu says the dish conversion has not been confirmed in living mice, and that he cannot yet rule out other neural stem cells having produced the extra neurons.
Why it matters
- constraint Because the nanogel depletes PTBP1 in brain cells generally rather than in astrocytes selectively, no amount of neuron-density data from this design can assign the new cells to astrocytes.
- capability A nanogel that carries protein-degrading antibodies into the brain is reusable against other targets, and that platform holds its value whether or not the PTBP1 conversion story survives.
- decision Groups weighing whether to keep PTBP1 on a target list must now judge a human in-vitro result against an unresolved in-vivo dispute, rather than settling it on behavioural endpoints.
- exposure Moving to primates and people within a few years would carry a mechanism whose cellular identity in living brains is unestablished into clinical planning, with network integration untested.
Alongside the higher neuron density, treated mouse brains showed less neuroinflammation and less amyloid-beta [11]. That complicates the reading of the behaviour. Nesting and maze performance in an amyloid model can improve when plaque load and inflammation come down, without a single support cell becoming anything. The behavioural readout measures function; it does not report where cells came from. Xu is candid on the point, telling Live Science that the dish result has not been confirmed in living mice and that other neural stem cells might also have converted [13].
Delivery gives a second reason for care. New Scientist reports the drug enters brain cells generally, including astrocytes, depletes PTBP1 inside them, and has its antibodies recycled by the cell after about a week [16]. PTBP1 is described as the master switch holding astrocytes back from a neuronal fate [4], so depleting it broadly leaves more than one plausible origin for the new neurons the team found sprouting in the hippocampus [12].
Then the denominator. Twelve engineered mice, half dosed and half given saline [22], which works out to six animals per arm [25]. Within that, the reported effect is not subtle: treated animals nested and ran the maze at the level of mice without the condition, while the saline group did not change [9]. Andras Lakatos at the University of Cambridge told New Scientist there is "clearly an improvement, which is very thought-provoking" [27]. Six per arm can carry a yes-or-no signal. It cannot carry durability or dose response, and it says nothing about how new neurons behave in a live circuit over months, which is what Benedikt Berninger at King's College London asks about [24].
The two write-ups also disagree on schedule. Live Science describes two intravenous doses eight days apart followed by four weeks of behavioural testing [10], while New Scientist describes two injections across two weeks with testing two weeks after that [22][9][30]. Anyone lining this up against the earlier literature needs the Aug. 26 Cell Biomaterials paper itself [15], not the coverage.
What is genuinely new here is human and in vitro: cultured human astrocytes and stem-cell organoids growing axons and firing synchronously [7], with no edit to the genome [2]. The 2020 work that opened this line used CRISPR to deplete PTBP1 in a Parkinson's mouse model and reported converted astrocytes [3]; tracing experiments afterwards could not connect the new neurons back to astrocytes [5]. In mice, this paper offers density plus behaviour, which is the same class of evidence that tracing overturned, so the in vivo burden has not moved. Christiane Wrann of Harvard Medical School, who was not involved, makes the same point about needing to follow an individual astrocyte [14]. In dishes of human cells, the burden has moved, and that is evidence the original dispute never had.
What to watch
- The planned mouse study with fluorescently tagged astrocytes: whether a labelled astrocyte is found carrying neuronal markers after treatment is the result that would settle the in vivo dispute.
- Whether nonhuman primate data appear before any move toward human trials, given Xu's stated timeline of a few years.
- Electrophysiology on the new neurons in place, answering Berninger's question about whether they join circuits without disrupting them.
Clarity's read
What the record supports and how the coverage leans. The claims behind it follow.
Reality
- Evidence44
- Adoption6
- Hype gap+34
- Incentives63
- Confidence61
Perspective Coverage
3 publishers- Builder
- Builder 45%
- Operator
- Operator 32%
- Investor
- Investor 23%
Claim ledger
Ranked by verification strength, evidence, and original report placement.
- [1]
Nano-ERASER is a polymer nanogel system that uses antibodies to degrade targeted proteins; the team used it to permeate the blood-brain barrier and enter astrocytes, where it deployed antibodies to break down PTBP1, triggering the astrocytes to convert to neurons.
- [2]
Compared with gene-editing tools like CRISPR, Nano-ERASER does not modify DNA, and its cell reprogramming is reversible.
- [3]
In 2020, scientists reported converting astrocytes into neurons in the brains of mice with a version of Parkinson's disease by using CRISPR to genetically engineer the mice to deplete PTBP1, which improved their motor skills.
- [4]
PTBP1 usually acts like a master switch that stops astrocytes from turning into neurons.
- [5]
Later experiments contradicted the earlier PTBP1 results, suggesting that newly formed neurons could not be traced back to the astrocytes.
- [6]
Xu on the conflicting literature: "We felt it's strange [that] two groups of people got different conclusions."
- [7]
Human astrocytes in lab dishes exposed to the gel lost their characteristic star shape and began forming axons, neuronal proteins became more abundant in them, and the cells later showed electrical activity and could fire synchronously; similar results were seen in organoids grown from human stem cells.
- [8]
The researchers applied Nano-ERASER to human astrocyte cultures and to human organoids designed to mimic brains with Alzheimer's disease; in both, PTBP1 levels fell and astrocytes converted to neurons that were functional.
- [9]
Two weeks later, mice given TN-PTBP1 were able to nest and navigate the maze at a similar level to a group of mice without the Alzheimer's-like condition, while the saline group showed no change.
- [10]
Live Science reports the team gave the mice two intravenous doses of the gel eight days apart, and that over the next four weeks behavioural tests suggested treated mice's memories improved and they built better nests than untreated mice.
- [11]
In treated mice, neuron density increased while levels of inflammatory molecules decreased, and the brains showed reduced neuroinflammation and reduced amyloid-beta buildup.
- [12]
Analysis of samples of the mice's hippocampi found that TN-PTBP1 had caused new neurons to sprout in the brain.
- [13]
Xu said that while the lab-dish experiments indicated astrocytes converted into neurons, that finding has not been confirmed in live mice: "we cannot yet eliminate the possibility that some other neural stem cells might have also converted into neurons."
- [14]
Christiane Wrann, a neuroscientist at Harvard Medical School who was not involved in the study, agreed that additional experiments would have been required to see whether a particular astrocyte in the mouse brain changed into a neuron, and said more research is needed on long-term effects on different brain cell types.
- [15]
The study was published Aug. 26 in the journal Cell Biomaterials.
- [16]
The drug enters cells in the brain, including astrocytes, where the antibodies bind to and substantially deplete PTBP1; after about a week the antibodies are recycled by the cell.
- [17]
Peisheng Xu, corresponding author, is a professor of pharmaceutics at the University of South Carolina.
- [18]
Xu says the team hopes to test the approach in monkeys and people in the next few years, and plans to evaluate the platform for longer-term efficacy before human clinical trials.
- [19]
Alzheimer's disease affects around 24 million people worldwide.
- [20]
Existing Alzheimer's treatments can slow disease progression but do not reverse cognitive decline.
- [21]
The adult brain has a limited capacity to produce new neurons at baseline and an even more limited ability to replace neurons lost to disease.
- [22]
The researchers tried the approach in 12 mice genetically engineered to develop a condition mimicking Alzheimer's, intravenously injecting half with TN-PTBP1 twice over two weeks while the rest received saline injections.
- [23]
The team is planning more studies in mice whose astrocytes are labelled with fluorescent tags, to track whether TN-PTBP1 is really behind those cells converting into neurons.
- [24]
The mice showed no signs of side effects, but Benedikt Berninger at King's College London said future work should explore whether the newly formed neurons safely integrate into the brain's networks without disrupting their function over the long term.
- [25]
The mouse experiment used six animals per arm.
- [26]
Wrann called the approach innovative and said the demonstration that the gel can cross the blood-brain barrier is important for developing therapies for the brain.
- [27]
Andras Lakatos at the University of Cambridge said of the mouse results: "There's clearly an improvement, which is very thought-provoking."
- [28]
Xu says the study does not prove that Nano-ERASER treats Alzheimer's disease in humans.
- [29]
Berninger said that with proper testing the potential of the drug could be huge and could have an enormous effect on the treatment of many brain diseases, including schizophrenia, motor neuron disease and Parkinson's.
- [30]
The two published accounts of the same experiment give different dosing and readout timings: eight days between doses with four weeks of subsequent behavioural testing in one, two doses across two weeks with testing two weeks later in the other.
Sources
3 independent publishers whose own reporting we read for this story.
- livescience.comScientists invent a gel that creates neurons from other cells, which could help treat Alzheimer's
1 article · August 28, 2026
- newscientist.comNanoparticles ease Alzheimer’s by making neurons from other cells
1 article · August 26, 2026
- phys.orgNanoparticles induce neuroregeneration in Alzheimer's disease models
1 article · August 26, 2026
Topics and entities
Follow any of these and your For You feed starts watching them — no settings page required.